Clinical trial NCT06589973: Effect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients
Official title: IImpact of Clinical and Biochemical Variables on Mortality and Morbidity of Patients With Alcohol Withdrawal Syndrome Under Treatment According to the CIWA-AR Scale"
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Alcohol Withdrawal Syndrome
Lead sponsor: Hospital General de Mexico
Sponsor class: OTHER_GOV
First posted: 2024-09-19
Enrollment: 195
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Clinical records (case files) of patients with an admission diagnosis of alcohol withdrawal syndrome (AWS) who have been treated in the Internal Medicine department for 5 years will be analyzed.

Brief summary: The goal of this observational study is to describe the impact measured through the Odds Ratio (OR) of different variables of clinical and biochemical alterations on the duration of the syndrome alcohol withdrawal patients measured in days of symptoms and stay; it could include any patients with a diagnosis of admission of alcohol withdrawal syndrome (AWS) who have been treated in the department of Internal Medicine for 5 years.

The main question it aims to answer is: What is the relationship between the different clinical, biochemical, and hematic factors on the duration of symptoms, morbidity, and mortality in individuals with alcohol syndrome withdrawal?

• If the patient has a greater number of risk factors, such as advanced age, a long and chronic history of alcohol consumption, the type of distillate consumed, as well as the deterioration of liver function and presence of leukocytosis and neutrophilia, then it is postulated that the duration of alcohol withdrawal syndrome will be longer.

Clinical records will be used to describe the proportion of complications associated with alcohol withdrawal syndrome including pneumonia bronchial aspiration, seizures, need for mechanical ventilation, digestive tract hemorrhage, toxic-alcoholic hepatitis, and pancreatitis.

Detailed description: Clinical records (files) of patients with a diagnosis of admission of alcohol withdrawal syndrome (AAS) who have been treated in the Department of Internal Medicine for 5 years.

Eligibility criteria: Inclusion Criteria:

* Clinical records of patients, both genders, over 18 years of age with Alcohol Withdrawal Syndrome according to the criteria for alcohol withdrawal.
* Clinical records of candidates for admission for neurological monitoring and with criteria for use of sedative drugs according to the CIWA-Ar scale
* Clinical records of patients containing the CIWA-Ar scale score at diagnosis

Exclusion Criteria:

* Clinical records of patients who already have a history of seizures or epilepsy
* Clinical records of diabetic patients with diabetic ketoacidosis
* Clinical records of patients who have not received any type of sedative treatment
* Clinical records of patients with chronic liver failure or liver cirrhosis
* Clinical records of patients with chronic liver disease with signs of hepatic encephalopathy
* Clinical records of patients with related toxic-alcoholic hepatitis
* Clinical records of patients with a life expectancy of less than 24 hours due to associated complications such as head trauma or other associated complications
* Clinical records of patients who require intubation and mechanical ventilation upon admission
* Clinical records of patients who have a vascular event that modifies the neurological evaluation
* Clinical records of patients who before admission show psychomotor alteration or neurological deterioration that modifies the neurological evaluation such as the presence of Wernicke's encephalopathy

Primary outcomes:
measure: Death
timeFrame: 6 months
measure: Morbidity
timeFrame: 6 months
Secondary outcomes:
measure: Hospital stay
timeFrame: 6 months
measure: Duration of symptoms
timeFrame: 6 months
Other outcomes:
Locations:
city: Mexico City
country: Mexico
facility: Hospital General de Cuautitlan "General José Vicente Villada"
Study officials:
References: